AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

PRESS RELEASE: Beth Israel Deaconess Medical Center initiates evaluation of Aastrom Biosciences' new dendritic cell vaccine product for cancer.

Chemical Business Newsbase

| April 24, 2001 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. (Hide copyright information)Copyright

Aastrom Biosciences Inc (Aastrom) has formalized an agreement with Beth Israel Deaconess Medical Center (BIDMC), Boston, MA to conduct external clinical beta site evaluations of Aastrom's new DC-I dendritic cell product for use in vaccines to treat various forms of cancer.

Aastrom selected researchers at BIDMC as its second US collaborator …

Related articles from newspapers, magazines, journals, and more
Aastrom Biosciences receives NIH grant for dendritic cell vaccine research.
News wire article from: Asia Africa Intelligence Wire September 15, 2003 700+ words
PRESS RELEASE: Aastrom Biosciences executes evalaution agreements with...
News wire article from: Chemical Business Newsbase April 24, 2001 700+ words
Aastrom Biosciences completes CE Mark requirements for third dendritic cell...
News wire article from: Asia Africa Intelligence Wire August 21, 2003 700+ words
Press Release: Aastrom Biosciences and Stanford University collaborate on...
News wire article from: Asia Africa Intelligence Wire October 2, 2002 700+ words
Aastrom's dendritic cell vaccine technology to be utilized in Duke...
News wire article from: Asia Africa Intelligence Wire December 11, 2003 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily